| acetylcysteine solution / Generic mfg. |
ACTRN12609000804280: The effect of N-acetylcysteine supplementation on cycling performance and adaptation to exercise in well-trained athletes |
|
|
| Not yet recruiting | 4 | 10 | | | University of Technology, Sydney, Australian Sports Commission | Exercise adaptation | | | | |
ACTRN12617000425392p: Can N-acetylcysteine (NAC) supplementation enhance exposure to altitude in well-trained cyclists? |
|
|
| Not yet recruiting | 4 | 12 | | | Australian Institute of Sport, Australian Institute of Sport | Exercise performance; Exercise induced inflammation; Altitude induced illness | | | | |
ACTRN12617000425392: Can N-acetylcysteine (NAC) supplementation enhance exposure to altitude in well-trained cyclists? |
|
|
| Not yet recruiting | 4 | 12 | | | Australian Institute of Sport, Australian Institute of Sport, NSW Institute of Sport, University Technology Sydney, Australian Catholic University | Exercise performance, Exercise induced inflammation, Altitude induced illness | | | | |
ACTRN12617000427370p: Can N-acetylcysteine (NAC) supplementation enhance altitude training in elite runners? |
|
|
| Not yet recruiting | 4 | 18 | | | Australian Institute of Sport, Australian Institute of Sport | Exercise Performance; Exercise induced inflammation; Altitude induced illness | | | | |
ACTRN12617000427370: Can N-acetylcysteine (NAC) supplementation enhance altitude training in elite runners? |
|
|
| Not yet recruiting | 4 | 18 | | | Australian Institute of Sport, Australian Institute of Sport, Athletics Australia, NSW Institute of Sport, University Technology Sydney, Australian Catholic University | Exercise Performance, Exercise induced inflammation, Altitude induced illness | | | | |
ACTRN12617000426381p: Can N-acetylcysteine (NAC) supplementation enhance altitude training in elite swimmers? |
|
|
| Not yet recruiting | 4 | 20 | | | Australian Institute of Sport, Australian Institute of Sport | Exercise performance; exercise induced inflammation; altitude induced illness | | | | |
ACTRN12617000426381: Can N-acetylcysteine (NAC) supplementation enhance altitude training in elite swimmers? |
|
|
| Not yet recruiting | 4 | 20 | | | Australian Institute of Sport, Australian Institute of Sport, Swimming Australia, NSW Institute of Sport, University Technology Sydney, Australian Catholic University | Exercise performance, exercise induced inflammation, altitude induced illness | | | | |
| Ongoing | 4 | 40 | Europe | Acetylcysteine, Effervescent tablet, Fluimucil Forte | Zambon SA, Zambon, SA | Postmenopausal health woman aged more than 50 years, Older woman, Body processes [G] - Immune system processes [G12] | | | | |
| Completed | 4 | 80 | | N-Acetylcysteine ;Capsule filled with amylum | Ningbo Addiction Research and Treatment Center; Level of the institution：, National Nature Science Foundation of China | Heroin addiction | | | | |
2011-002093-23: Absorption of drug N acetylcysteine from gastrointestinal system in severely ill patients Ravimi atsetüültsüsteiini imendumine väga raskelt haigete patsientide soolestikust |
|
|
| Ongoing | 4 | 60 | Europe | N-acetylcysteine, Dispersible tablet, Solution for injection | University of Tartu, University of Tartu | Severe neurotrauma, severe pulmonary infections and severe gastrointestinal disease (eg peritonitis, pancreatitis, ileus, major abdominal surgery etc). Need for liquefaction of viscous sputum, Severe affections of different organ systems: nervous system, lungs and stomach. Need for sputum liquefaction., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ChiCTR-TRC-14004578: Efficacy of high dose N-acetylcysteine on Obstructive Sleep Apnea Symptom (OSAS) and the comorbidity: A Prospective multicenter, randomized, double-blind, placebo-controlled study |
|
|
| Completed | 4 | 300 | | N-acetylcysteine 1200mg (600mg, twice daily) ;Placebo | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, National Science & Technology Pillar Program during the Twelfth Five-year Plan Period, Code 2012BAI05B02 | Obstructive Sleep Apnea Symptom | | | | |
2006-006815-62: Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery? A prospective randomised controlled trial. |
|
|
| Ongoing | 4 | 224 | Europe | Acetylcysteine, Parvolex, Parvolex | University Hospitals of South Manchester NHS Foundation Trust | Renal impairment after coronary artery byapass surgery | | | | |
2008-004613-10: The role of the antioxidants ascorbic acid and n-acetylcysteine in the attenuation of ischaemia reperfusion injury in a human model |
|
|
| Ongoing | 4 | 90 | Europe | Parvolex, Rubex effervescent, Parvolex, Rubex effervescent, Parvolex | University College Hospital Galway | Ischaemia reperfusion injury | | | | |
2009-014534-15: EFFECT OF ACUTE ADMINISTRATION OF N-ACETYLCYSTEINE ON BLOOD PRESSURE OF PULMONARY ARTERIAL IN PRIMARY PULMONARY HYPERTENSION. |
|
|
| Ongoing | 4 | 30 | Europe | FLUIMUCIL FIALE*6F 300MG/3ML, FLUIMUCIL FIALE*6F 300MG/3ML | AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\" | PRIMARY PULMONARY HYPERTENSION | | | | |
ChiCTR-TRC-14005169: Effect of inhaled N-acetylcysteine on the pulmonary complications after liver transplantation |
|
|
| Recruiting | 4 | 300 | | Atomization inhalation of N-acetylcysteine ;none ;Atomization inhalation of Sterile Water for Injection | 3rd Affiliated Hospital, Sun Yat-sen University; 3rd Affiliated Hospital, Sun Yat-sen University, self-financing | liver disease | | | | |
ChiCTR-OPC-17012837: The study of N-acetylcysteine's effective on gastric juice in vitro and in vivo |
|
|
| Recruiting | 4 | 50 | | water+gastric juice ;Streptavidin+gastric juice ;NAC+gastric juice ;Streptavidin+water+gastric juice ;Streptavidin+gastric juice+NAC | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, self- financing | Chronic Gastritis | | | | |
ChiCTR-IPR-15007616: Efficacy and safety of inhaled N-acetylcysteine on exacerbation of chronic obstructive pulmonary disease (AECOPD), a randomized controlled trial |
|
|
| Recruiting | 4 | 400 | | Inhaled N-acetylcysteine 600 mg (300 twice a day) ;Inhaled NS 6ml (3ml twice a day) | Affiliated Hospital of Chengdu University; Affiliated Hospital of Chengdu University, Self-funding project | chronic obstructive pulmonary disease (COPD) | | | | |
2016-003144-36: reduction in pain after surgery by giving N-Acetylcysteïne before surgery vermindering van postoperatieve pijn door voor de operatie NAcetylcysteïne te geven |
|
|
| Not yet recruiting | 4 | 60 | Europe | Acetylcysteine, RVG 10903, Infusion, acetylcysteine | Radboud University Medical Centre, Radboud University Medical Centre | postoperative pain postoperatieve pijn, pain after surgery pijn na operatie, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] | | | | |
ChiCTR1800015281: Efficacy of Premedication with N-acetylcysteine during Upper Gastrointestinal Endoscopy Examation |
|
|
| Not yet recruiting | 4 | 1200 | | Lidocaine gel ;pronase+simethicone ;600mg N-acetylcysteine ;1200mg N-acetylcysteine | Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Private Expenses | early cancer of upper digestive tract | | | | |
ChiCTR2000030583: A randomized controlled trial for N-acetylcysteine in the treatment of severe alcoholic hepatitis |
|
|
| Recruiting | 4 | 170 | | Combined with NAC on the basis of comprehensive medicine ;Comprehensive medical treatment | The fifth medical center of PLA General Hospital; The Fifth Medical Center of PLA general hospital, The Fund of Beijing Science and Technology Planning Project | severe alcoholic hepatitis | | | | |
2019-004463-44: Injection of N-acetylcysteine through the eardrum to reduce hearing loss related to Cisplatin chemotherapy. |
|
|
| Not yet recruiting | 4 | 86 | Europe | Lysomucil, Solution for injection, Lysomucil® | CHU Saint Pierre, ENT and H&N Surgery department - CHU Saint-Pierre | Ototoxicity, Ototoxicity, Diseases [C] - Cancer [C04] | | | | |
2020-004549-35: Usefulness of the use of N-Acetylcysteine associated with conventional treatment in patients with severe alcoholic hepatitis (Maddrey> = 32) Utilidad del uso de N-Acetilcisteína asociado ala tratamiento convencional en pacientes con Hepatitis alcohólica grave (Maddrey>=32) |
|
|
| Not yet recruiting | 4 | 390 | Europe | Tablet, Solution for injection, Powder for oral solution, Powder for injection, Urbason 16mg, Flumil 100 mg/ml solución inyectable, Fluimucil 200 mg granulado para solución oral, Metilprednisolona Normon 40 mg polvo y disolvente para solución inyectable EFG, Prednisona cinfa 30 mg comprimidos EFG | University Hospital Of Araba, University Hospital of Araba | Alcoholic hepatitis Hepatitis alcohólica, Alcoholic hepatitis Hepatitis alcohólica, Diseases [C] - Digestive System Diseases [C06] | | | | |
ChiCTR-IIR-17012604: Long-term regular treatment of early COPD with Acetylcysteine effervescent tablets: a randomized, double-blind, placebo-controlled multicenter clinical study |
|
|
| Recruiting | 4 | 1000 | | N-acetylcysteine effervescent tablets ;Placebo | The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Ministry of Science and Technology, China | Chronic Obstructive Pulmonary Disease | | | | |
ChiCTR2000040505: N-acetylcysteine in children with biliary atresia: a clinical trial |
|
|
| Not yet recruiting | 4 | 80 | | N-Acetylcysteine ;N-Acetylcysteine ;Conventional therapy ;Conventional therapy | Guangzhou Women and Children Medical Center; Guangzhou Women and Children Medical Center, Natural Science Foundation of China | biliary atresia | | | | |
| Recruiting | 4 | 75 | Europe | N-acetylcysteine, Placebo Oral Tablet, Magnetic Resonance Imaging, Neurocognitive measures, Neuro-inflammatory measures | Universitair Ziekenhuis Brussel | Cannabis Use Disorder, Cannabis Dependence | 02/22 | 02/23 | | |
ACTS, NCT04460521: The Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome |
|
|
| Recruiting | 4 | 240 | Canada | N-Acetyl cysteine, Wrist Splint | Emily Krauss | Carpal Tunnel Syndrome, Hand Injuries and Disorders, Nerve Compression, Splints, Carpal Tunnel, Carpal Tunnel Release | 04/26 | 10/26 | | |
NAC2, NCT02505477: Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine |
|
|
| Completed | 4 | 51 | US | N-acetylcysteine, NAC, acetylcysteine, cysteine, Acetadote, Treatment as Usual | University of California, Los Angeles | Schizophrenia, Cognitive Deficits, Schizophrenia; Negative Type | 01/23 | 01/23 | | |
NCT04226456: Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity |
|
|
| Terminated | 4 | 19 | Europe | N-acetyl cysteine, Lysomucil 10% | Centre Hospitalier Universitaire Saint Pierre | Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral, Ototoxicity, Tinnitus | 05/23 | 09/23 | | |
NCT05903014: Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction |
|
|
| Recruiting | 4 | 88 | RoW | n-acetylcysteine, Motivational Enhancement Therapy | Indonesia University | Nicotine Dependence, Nicotine Addiction | 09/23 | 12/23 | | |
NCT03757585: Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD) |
|
|
| Recruiting | 4 | 60 | US | Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine | Massachusetts General Hospital, Demarest Lloyd Jr. Foundation | Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism | 07/24 | 07/24 | | |
NCT03652753: Pilon Fracture With Intra-articular Injection of N-Acetylcysteine (Pilon NAC) |
|
|
| Recruiting | 4 | 30 | US | N-acetylcysteine, Saline | University of Missouri-Columbia | Pilon Fracture | 01/25 | 01/25 | | |
NCT03911414: A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth |
|
|
| Recruiting | 4 | 60 | US | Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine | Massachusetts General Hospital | Mood Disturbance, Mood Disorders, Natural Supplements, Alternative Treatment | 01/25 | 01/25 | | |
| Recruiting | 4 | 30 | US | n-acetylcystine + albuterol, Mucomyst, NAC, n-acetylcystine, 0.9% saline + albuterol, Normal saline | University of California, San Francisco | Asthma | 03/24 | 03/24 | | |
ChiCTR2200058813: N-acetylcysteine as an add-on to antituberculosis chemotherapy and QB-Spot as an efficacy monitoring method in pulmonary tuberculosis patients: a prospective, single center, open label, randomized controlled trial |
|
|
| Not yet recruiting | 4 | 28 | | N-acetylcysteine as an add-on to antituberculosis chemotherapy ;Antituberculosis chemotherapy | Henan Chest Hospital; Henan Chest Hospital, 2021 Henan Province Medical Science and Technology Tackling Program Joint Co-Construction Project | Pulmonary tuberculosis | | | | |
NCT06384833: Combination of Vitamin C and N-Acetylcysteine to Improve Functional Outcome After Rotator Cuff Repair |
|
|
| Not yet recruiting | 4 | 110 | NA | Ascorbic acid, Vitamin C, N-acetyl cysteine, NAC, placebo | Mahidol University | Rotator Cuff Tears | 09/25 | 05/26 | | |
NAC, NCT06486805: N-Acetyl Cysteine Effect on Liver Function After Mitral Valve Replacement |
|
|
| Recruiting | 4 | 34 | RoW | N acetyl cysteine, NAC, normal saline, placebo | Kasr El Aini Hospital | Oxidative Stress, Liver Dysfunction | 09/24 | 10/24 | | |
TEAM, NCT06152653: The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC |
|
|
| Recruiting | 4 | 20 | US | n-acetylcystine (NAC)+ albuterol, Mucomyst, NAC, AeroEclipse-VersaPAP System, VersaPAP System | University of California, San Francisco, National Heart, Lung, and Blood Institute (NHLBI) | Asthma, COPD | 11/27 | 11/27 | | |
NCT05944458: The Effect of NAC in Decreasing the Incidence of Linezolid-induced Thrombocytopenia in Critically Ill Patients |
|
|
| Recruiting | 4 | 112 | RoW | N acetyl cysteine, Fluimucil, NAC | Helwan University | Linezolid Induced Thrombocytopenia | 08/24 | 08/24 | | |
NCT06546475: A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine |
|
|
| Not yet recruiting | 4 | 20 | NA | N-Acetylcysteine, N-Acetylcysteine 2400 mg/d | National Taiwan University Hospital | Psychosis | 07/27 | 07/27 | | |
| Recruiting | 4 | 60 | US | N-Acetyl cysteine, NAC, Placebo comparator, Cognitive behavioral therapy (CBT), CBT | Ellen Herbst, Tobacco Related Disease Research Program | Cannabis Use, Tobacco Use Disorder, Drug Use Disorder | 06/25 | 06/25 | | |
NCT05408247: A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder |
|
|
| Recruiting | 4 | 280 | RoW | N-acetyl cysteine, NAC, Placebo | University of Sydney, Monash University | Alcohol Use Disorder (AUD) | 11/25 | 11/26 | | |
NCT06083480: Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty |
|
|
| Not yet recruiting | 4 | 148 | US | GlyNAC (combination of glycine and n-acetylcysteine), GlyNAC, Placebo | Vanderbilt University Medical Center, National Institute on Aging (NIA) | Osteoarthritis, Knee, Total Knee Arthroplasty, Chronic Postsurgical Pain | 09/28 | 03/29 | | |
ACTRN12618000413224: The efficacy and mechanisms of action of N-acetylcysteine as an adjunct treatment for first episode psychosis. |
|
|
| Recruiting | 3/4 | 162 | | | Orygen, The National Centre of Excellence in Youth Mental Health, National Health and Medical Research Council | First episode psychosis | | | | |
ACTRN12615001339549: Effect on Migraine Frequency of using Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC): The MIGRANT study. |
|
|
| Recruiting | 3 | 84 | | | University of Notre Dame Australia, Fremantle Hospital Medical Research Foundation | Migraine, Headaches | | | | |
ACTRN12606000088549: Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgery |
|
|
| Recruiting | 3 | 200 | | | Prince of Wales Hospital, Intensive care research fund | Renal Impairment in cardiac surgery | | | | |
ACTRN12619001549112: The NACSTOP 2 trial: Investigation of the early cessation of N-acetylcysteine in patients following paracetamol overdose. |
|
|
| Recruiting | 3 | 200 | | | Monash Health, Monash Health | paracetamol overdose | | | | |
ACTRN12619001548123: Double NAC trial: Investigation of increased N-acetylcysteine dosing in patients treated for paracetamol overdose. |
|
|
| Recruiting | 3 | 230 | | | Monash Health, Monash Health | paracetamol overdose | | | | |
2014-004522-17: Why might NAC (N-Acetylcysteine) reduce the risk of infection in alcoholic hepatitis? |
|
|
| Ongoing | 3 | 42 | Europe | Acetylcysteine, Prednisolone, Solution for injection/infusion, Tablet, NAC, Prenisolone | Imperial College London & Imperial College Healthcare NHS Trust, Imperial College NIHR BRC funding | Alcoholic hepatitis, Liver inflammation caused by excessive alcohol drinkng, Body processes [G] - Immune system processes [G12] | | | | |
2005-003651-12: NAC EFFECT ON OXIDATIVE STRESS AND MUSCLE FUNCTION IN COPD PATIENTS.Efecto de NAC en estrés oxidativo y función muscular en pacientes con EPOC |
|
|
| Ongoing | 3 | 14 | Europe | N-Acetylcysteine, FLUMIL, FLUMIL | ZAMBON, S.A. | CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). | | | | |
2006-003957-25: Rare Diseases with microvascular involvement. High Dose Intravenous N-acetylcysteine versus Iloprost for early, rapidlyprogressive diffuse Systemic Sclerosis (Scleroderma) |
|
|
| Ongoing | 3 | 45 | Europe | HIDONAC*EV 1FL 5G 25ML, ENDOPROST 50*INFUS 1F 0,050MG/, HIDONAC*EV 1FL 5G 25ML, ENDOPROST 50*INFUS 1F 0,050MG/ | AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI | Systemic Scleroderma | | | | |
2010-022994-32: Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease |
|
|
| Ongoing | 3 | 48 | Europe | Acetylcysteine, Acetylcysteine, Acetylcysteine | UMC Utrecht | Chronic kidney diseaseEnd stage renal disease | | | | |
2012-005435-87: EFFECT OF ADJUVANT TREATMENT WITH N - ACETYLCYSTEINE DURING 48 WEEKS ON THE LOSS OF GREY SUBSTANCE AND OXIDATIVE METABOLISM IN PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES: BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL EFECTO DEL TRATAMIENTO ADYUVANTE CON N - ACETILCISTEÍNA DURANTE 48 SEMANAS SOBRE LA PÉRDIDA DE SUSTANCIA GRIS Y EL METABOLISMO OXIDATIVO EN PACIENTES CON PRIMEROS EPISODIOS PSICÓTICOS DE INICIO TEMPRANO: ENSAYO CLÍNICO ALEATORIZADO, DOBLE-CIEGO, CONTROLADO CON PLACEBO |
|
|
| Ongoing | 3 | 90 | Europe | N-acetylcysteine, ACETILCISTEINA FARMASIERRA 600 mg, ACETILCISTEINA FARMASIERRA 600 mg | Fundación para la Investigación Biomédica Hospital Gregorio Marañón, Fundación para la Investigación Biomédica Hospital Gregorio Marañón | PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES PACIENTES CON PRIMEROS EPISODIOS PSICÓTICOS DE INICIO TEMPRANO | | | | |
2020-002531-30: ETUDE DE TOLERANCE DE LA N-ACETYLCYSTEINE POUR LA THROMBOLYSE A LA PHASE AIGUË DE L’INFARCTUS CEREBRAL ETUDE DE TOLERANCE DE LA N-ACETYLCYSTEINE POUR LA THROMBOLYSE A LA PHASE AIGUË DE L’INFARCTUS CEREBRAL |
|
|
| Not yet recruiting | 3 | 19 | Europe | HIDONAC, Solution for infusion, HIDONAC | CHU CAEN Normandie, CHU CAEN Normandie | Patients atteints d’un infarctus cérébral non lacunaire bénéficiant d’un traitement par fibrinolyse intraveineuse (+/- thrombectomie mécanique). Patients atteints d’un infarctus cérébral non lacunaire bénéficiant d’un traitement par fibrinolyse intraveineuse (+/- thrombectomie mécanique)., Patients atteints d’un infarctus cérébral non lacunaire bénéficiant d’un traitement par fibrinolyse intraveineuse (+/- thrombectomie mécanique). Patients atteints d’un infarctus cérébral non lacunaire bénéficiant d’un traitement par fibrinolyse intraveineuse (+/- thrombectomie mécanique)., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Recruiting | 3 | 42 | Europe | N-acetyl cysteine (NAC), NAC | Imperial College London | Alcoholic Hepatitis, Infection | 04/22 | 06/25 | | |
| Not yet recruiting | 3 | 219 | RoW | Vitamin C, N-acetylcysteine (NAC), NAC + Bromhexine (BMX) | Universidade Federal do Ceara, Paulista School of Medicine-EPM, UNIFESP, Health Surveillance Secretariat - SVS, Central Laboratory of Public Health of Ceara - LACEN-CE, Leonardo da Vinci Hospital - HLV, São José Hospital for Infectious Diseases - HSJ, Ceará Health Secretariat - SESA, Municipal Health Secretary - SMS-Fortaleza | COVID-19 | 04/22 | 06/22 | | |
NCT03557229: Clinical Trial of Antioxidant Therapy in Patients With Septic Shock |
|
|
| Active, not recruiting | 3 | 131 | RoW | Melatonin 5 mg, Vitamin C 1 GM Oral Tablet, Vitamin E 400 UNT, N-acetylcysteine | American British Cowdray Medical Center | Oxidative Stress, Septic Shock | 06/22 | 06/22 | | |
NCT05801055: A Study to Evaluate Endoscopic Visibility of Stomach After a Combination Drink of N-acetylcysteine and Simethicone |
|
|
| Not yet recruiting | 3 | 200 | RoW | Evaluation of gastric visibility following the combination drink of N-acetyle cysteine and simethocone | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Gastric Disease | 06/23 | 06/23 | | |
NCT00585559: Acetaminophen in aSAH to Inhibit Lipid Peroxidation and Cerebral Vasospasm |
|
|
| Terminated | 3 | 120 | US | Placebos for acetaminophen and N-acetylcysteine, APAP 1 gm every 6 hours and N-acetylcysteine placebo, NAC IV infusion at 0.5 gm hourly and APAP placebo, APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly, APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly | Vanderbilt University Medical Center, National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) | Aneurysmal Subarachnoid Hemorrhage, Cerebral Vasospasm | 10/23 | 10/23 | | |
NCT06165068: Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study |
|
|
| Recruiting | 3 | 174 | RoW | Aspirin 81Mg Ec Tab, Clopidogrel, N-acetylcysteine, NAC-long | Navamindradhiraj University | Dry Age-related Macular Degeneration | 12/25 | 09/26 | | |
NCT06236165: Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of Both N-acetylcysteine and Pentoxifylline Supplementation in Patients With Hepatic and Post Hepatic Jaundice |
|
|
| Recruiting | 3 | 66 | RoW | N-acetylcysteine, Pentoxifylline | Tanta University | Hepatic and Post Hepatic Jaundice | 08/24 | 02/25 | | |
NCT02750319: Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery |
|
|
| Active, not recruiting | 3 | 184 | US | Amiodarone, N-Acetylcysteine, Placebo | Memorial Sloan Kettering Cancer Center, Washington University School of Medicine, The Cleveland Clinic, Vanderbilt University School of Medicine | Thoracic Surgery, Atrial Fibrillation in High Risk Patients | 04/25 | 04/25 | | |
NCT05907486: The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation |
|
|
| Not yet recruiting | 3 | 260 | NA | N-acetyl-cysteine, NAC, Busulfan, BU, Cytarabine, Ara-C, Cyclophosphamide, CTX | The First Affiliated Hospital of Soochow University | Thrombotic Disorder | 08/25 | 12/25 | | |
| Recruiting | 3 | 240 | US | IV N-acetylcysteine, NAC, IV Placebo, Placebo | Medical University of South Carolina | Hysterectomy | 09/25 | 10/25 | | |
NCT05706402: N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD |
|
|
| Recruiting | 3 | 80 | RoW | N-acetylcysteine, Placebo | Queen Mary Hospital, Hong Kong | Chronic Obstructive Pulmonary Disease | 09/25 | 09/25 | | |
NCT03900988: Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and Pneumonia |
|
|
| Recruiting | 3 | 160 | RoW | N-acetyl cysteine, 5% Dextrose | Chinese University of Hong Kong | Influenza | 10/25 | 12/25 | | |
ChiCTR2300070042: Comparative study on the effect of different drugs on relieving discomfort caused by Lugo's iodine staining in esophagus |
|
|
| Recruiting | 3 | 300 | | normal saline; N-acetylcysteine solution; Vitamin C solution | Shihezi University First Affiliated Hospital; Shihezi University First Affiliated Hospital, Science and Technology Bureau of the XPCC southward development project | Early esophageal neoplasms and precancerous lesions | | | | |
| Recruiting | 3 | 438 | Europe, Canada, US, RoW | N-acetylcysteine, Placebo | Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania | Retinitis Pigmentosa | 12/28 | 12/28 | | |
NCT05738681: Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial |
|
|
| Recruiting | 2/3 | 82 | RoW | N acetyl cysteine, Standard anti TB drug regimen | Mahidol University | Tuberculosis, Drug Induced Liver Injury, Hepatitis | 03/23 | 05/23 | | |
NCT03055377: N-Acetylcysteine for Youth Cannabis Use Disorder |
|
|
| Completed | 2/3 | 192 | US | N-acetyl cysteine, Placebo oral capsule | Medical University of South Carolina | Cannabis Use Disorder | 01/24 | 02/24 | | |
NCT05664789: Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial |
|
|
| Recruiting | 2/3 | 48 | US | N acetyl cysteine, Placebo | Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Autism Spectrum Disorder | 01/26 | 01/26 | | |
NCT05494398: Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label |
|
|
| Enrolling by invitation | 2/3 | 48 | US | N-acetylcysteine | Stanford University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Autism Spectrum Disorder | 09/27 | 09/28 | | |
ACTRN12611000766910: Clinical effects of N-acetylcysteine in the treatment of acute decompensated heart failure |
|
|
| Recruiting | 2 | 70 | | | Alfred Health, Supported as a part of NHMRC Program Grant | Acute decompensated heart failure | | | | |
ACTRN12614000411640: The Post Anaesthesia N-Acetycysteine Cognitive Evaluation trial, investigating the potential for N-Acetylcysteine to reduce cognitive dysfunction following major elective non-cardiac surgery |
|
|
| Recruiting | 2 | 370 | | | The Geelong Hospital, The Geelong Hospital, CRC for Mental Health, Sydney Parker Smith Scholarship | Post Operative Cognitive Dysfunction
, Surgical Stress Response, Post Operative Mood Disorder, Post surgical pain | | | | |
ACTRN12616000781448: Can use of N-acetylcysteine and Ramipril improve clinical outcomes in Tako Tsubo Cardiomyopathy (TTC) patients? A randomised controlled trial. |
|
|
| Recruiting | 2 | 100 | | | Cardiology Department, Queen Elizabeth Hospital , Cardiology Department, Queen Elizabeth Hospital | Takotsubo Cardiomyopathy | | | | |
2005-001525-28: INFLUENCE OF THE ANTIOXIDANT N-ACETYLCYSTEINE ON INHALED NITRIC OXIDE INDUCED PULMONARY RESPONSES FOLLOWING HUMAN LUNG ISCHAEMIA-REPERFUSION INJURY |
|
|
| Ongoing | 2 | 43 | Europe | INOmax® (nitric oxide), ACETYLCYSTEINE 200MG/ML INJECTION, | Imperial College London | heart-lung transplantation | | | | |
2008-000955-90: Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclerosis patients |
|
|
| Ongoing | 2 | 80 | Europe | n-acetylcysteine, | ISTITUTO C. MONDINO | multiple sclerosis | | | | |
| Ongoing | 2 | 10 | Europe | fluimicil, fluimicil | Academic Medical Centre | Patients homozygous for sickle cell disease | | | | |
2008-005015-17: Effect of N-acetylcysteine on thiopurine related hepatotoxicity in IBD patients |
|
|
| Ongoing | 2 | 30 | Europe | acetylcysteine, acetylcysteine, acetylcysteine | VU university medical centre | adult patients (18-70 years old) who have been treated with azathioprine, 6-mercaptopure or 6-thioguanine for inflammatory bowel disease, in whom hepatotoxicity occured as an adverse event, are eligible. Prior to definite inclusion, the patients will be screened to make other causes of hepatotoxicity less likely. | | | | |
2013-001097-24: Trial of cleansing drink to improve visualisation during gastroscopy |
|
|
| Ongoing | 2 | 126 | Europe | Parvolex, Simeticone, Parvolex, Infacol, Parvolex, Infacol | Portsmouth Hospitals NHS trust, Portsmouth Hospitals NHS Trust | Early gastrointestinal lesions in the upper gastrointestinal tract.Our study is not looking at the direct treatment of any particular condition, but the early detecton of lesions. When performing upper gastrointestinal endoscopy it is a common problem to find views obscured by mucous and foam. We therefore intend to use n-acetyl cysteine and Simeticone as a mucolytic agent, potentially improving views of the mucosa and therefore enabling early detection of small lesions. | | | | |
2018-000420-34: Efficacy of N-acetylcysteine on the craving symptoms of hospitalized patients with cocaine addiction. Etude de l’efficacité de la N-acetylcysteine sur les symptômes de manque (craving) de patients cocaïnomanes abstinents hospitalisés. |
|
|
| Not yet recruiting | 2 | 80 | Europe | Tablet, Lysomucil 600 mg | Centre Hospitalier Universitaire Brugmann, CHU Brugmann | Cocaine addiction, Cocaine addiction, Psychiatry and Psychology [F] - Behaviours [F01] | | | | |
2019-001995-12: Protection offered by N-Acetylcysteine against radiation induced cellular damage in patients undergoing ablation procedures because of cardiac arrhythmia. Protezione della N-acetilcisteina contro i danni cellulari indotti dalle radiazioni in pazienti trattati con procedura di ablazione guidata da raggi X per aritmie cardiache. |
|
|
| Ongoing | 2 | 550 | Europe | ACETILCISTEINA EG, [ACETILCISTEINA EG], Solution for injection, ACETILCISTEINA EG - 300 MG/3 ML SOLUZIONE INIETTABILE E DA NEBULIZZARE 5 FIALE | CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO, Ministero della Salute – Ricerca Finalizzata – Codice Progetto RF – 2018- 12367090 | Patients with Cardiac Arrhythmia who undergo catheter ablation procedures guided by x-Ray imaging Pazienti con aritmia cardiaca candidati a trattamento con procedura di ablazione transcatetere, guidata da raggi X., Patients with Cardiac Arrhythmia who undergo catheter ablation procedures guided by x-Ray imaging Pazienti con aritmia cardiaca candidati a trattamento con procedura di ablazione transcatetere, guidata da raggi X., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NF1NAC, NCT04481035: Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 |
|
|
| Active, not recruiting | 2 | 5 | US | N-acetylcysteine (NAC), Chemical Name: Cysteine, N-acetyl-, L, Commercial Name(s): Acetein; Acetadote, Acetylcysteine; Airbron; Broncholysin; Fluimucetin; Fluimucil; Inspir; Mucofilin; Mucomyst; Mucosolvin; NAC; Paravolex; Respaire, Synonym:L-alpha-acetamido-beta-mercaptopropionic acid; Mercapturic acid; N-Acetyl-3-mercaptoalanine; N-Acetylcysteine, Placebo | Children's Hospital Medical Center, Cincinnati | Neurofibromatosis 1 | 06/20 | 01/26 | | |
2019-004188-35: Time-dependent activity of N-acetylcysteine on plasma antioxidant capacity in subjects with redox unbalance-Studio CAPITAL Effetto tempo-dipendente dell’N-acetilcisteina sulla capacità antiossidante del plasma in soggetti con stato ossidativo alterato- Studio CAPITAL |
|
|
| Ongoing | 2 | 6 | Europe | ACETILCISTEINA - 300 MG/3 ML SOLUZIONE INIETTABILE E PER NEBULIZZATORE E PER ISTILLAZIONE ENDOTRACHE, FLUIMUCIL 600 MG GRANULATO PER SOLUZIONE ORALE, [ACETILCISTEINA - 300 MG/3 ML SOLUZIONE INIETTABIL, [FLUIMUCIL 600 MG GRANULATO PER SOLUZIONE ORALE], Solution for injection, Granules for oral solution, ACETILCISTEINA EG - 300 MG/3 ML SOLUZIONE INIETTABILE E DA NEBULIZZARE 5 FIALE, FLUIMUCIL - 600 MG GRANULATO PER SOLUZIONE ORALE 30 BUSTINE | CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO | ARTERIAL HYPERTENSION IPERTENSIONE ARTERIOSA, ARTERIAL HYPERTENSION IPERTENSIONE ARTERIOSA, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-003232-80: RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine : A Randomized, Double-blind, Placebo-controlled, Cross-over Trial RENACTIF : Réduction par la N-AcétylCystéine d’un mécanisme Thrombotique dans l’Insuffisance rénale : Essai randomisé, en double aveugle, contrôlé-placebo, cross-over |
|
|
| Not yet recruiting | 2 | 40 | Europe | N-AcetylCysteine, N-AcetylCysteine, Solution for infusion, HIDONAC 5 g/25 ml | ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE, ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE | Chronic Kidney Disease maladie rénale chronique, Chronic Kidney Disease maladie rénale chronique, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Completed | 2 | 190 | | | Austin Health, Defence Health Foundation , Sir Edward Dunlop Medical Research Foundation | post traumatic stress disorder | | | | |
| Recruiting | 2 | 110 | RoW | N-acetyl cysteine, NAC | The Aurum Institute NPC, National Institute for Medical Research, Tanzania | Tuberculosis, Pulmonary | 12/21 | 12/21 | | |
NCT04864496: Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa |
|
|
| Active, not recruiting | 2 | 30 | RoW | Prescribe N-acetylcysteine tablets, Prescribe placebo tablets | Shahid Beheshti University of Medical Sciences | Retinitis Pigmentosa | 03/22 | 12/22 | | |
| Not yet recruiting | 2 | 19 | Europe | N-Acetyl cysteine, HIDONAC | University Hospital, Caen | Stroke, Ischemic | 06/22 | 09/22 | | |
NCT03499249: N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy |
|
|
| Completed | 2 | 13 | US | N-Acetyl cysteine | Baylor College of Medicine | Biliary Atresia | 10/22 | 03/24 | | |
NCT03220776: Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics |
|
|
| Completed | 2 | 54 | US | N-Acetylcysteine, Gabapentin, Placebo Oral Tablet | Medical University of South Carolina, National Institutes of Health (NIH), National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder, Bipolar Disorder | 11/22 | 11/22 | | |
NACoV, NCT05736887: Exploratory Efficacy of N-Acetylcysteine in Patients With History of COVID-19 |
|
|
| Active, not recruiting | 2 | 80 | Europe | N-Acetylcysteine, Placebo | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | COVID-19 | 01/23 | 06/23 | | |
NCT04918719: Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke |
|
|
| Not yet recruiting | 2 | 118 | NA | Acetylcysteine, N-acetylcysteine, Dextrose in Water, D5W, 5% Dextrose in Water | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Acute Ischemic Stroke | 01/23 | 03/23 | | |
ALISON, NCT04712435: Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation |
|
|
| Not yet recruiting | 2 | 80 | RoW | N-acetylcysteine, Placebo | Instituto Brasileiro de Controle do Cancer | Sinusoidal Obstruction Syndrome (SOS), Hematopoietic Stem Cell Transplant (HSCT) | 03/23 | 03/23 | | |
NCT05340504: Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder |
|
|
| Completed | 2 | 12 | US | N-Acetyl cysteine, Placebo | Medical University of South Carolina, Milken Institute | Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder | 06/23 | 06/23 | | |
NCT03306979: Memory and Antioxidants in Vascular Impairment Trial |
|
|
| Completed | 2 | 60 | Canada | N Acetylcysteine, NPN 80004844, Placebo oral capsule, Placebo | Sunnybrook Health Sciences Centre | Vascular Cognitive Impairment no Dementia | 09/23 | 09/23 | | |
NCT05557448: To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose |
|
|
| Recruiting | 2 | 24 | RoW | TYNADOTE, Placebo Oral Tablet | Sinew Pharma Inc., Taipei Veterans General Hospital, Taiwan | Hepatitis | 12/26 | 12/26 | | |
NCT06297369: Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients |
|
|
| Recruiting | 2 | 60 | RoW | N acetyl cysteine | Ain Shams University | Cisplatin Adverse Reaction, Cisplatin Nephrotoxicity, Cisplatin Induced Peripheral Neuropathy, Cancer Patients, Cisplatin Ototoxicity | 02/25 | 08/25 | | |
NCT06354712: Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients. |
|
|
| Recruiting | 2 | 50 | RoW | N-Acetyl-Cysteine with Institutional standard care, Institutional standard care | Mansoura University | Oral Mucositis (Ulcerative) Due to Radiation | 03/25 | 03/25 | | |
NCT03707951: N-Acetylcysteine for Adolescent Alcohol Use Disorder |
|
|
| Completed | 2 | 120 | US | N-acetylcysteine, Placebo oral capsule | Medical University of South Carolina | Alcohol Use Disorder | 02/24 | 02/24 | | |
NCT04291209: Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity. |
|
|
| Recruiting | 2 | 80 | Canada | N-Acetyl Cysteine, NAC | Sunnybrook Health Sciences Centre, Toronto Sunnybrook Regional Cancer Centre, London Regional Cancer Program, Canada | Ototoxic Hearing Loss | 05/24 | 05/24 | | |
